NUMAFERM GmbH was founded in 2017 as a spin-off of the Biochemistry Institute at the Heinrich-Heine University, Dusseldorf. The project was previously supported by an EXIST research transfer from the German Federal Ministry of Economics and Energy. The company offers its technology, related R&D services and a peptide catalogue focusing on pharmaceutical, antimicrobial and adhesives peptides.

Press releases

27. May 2021

Full speed ahead in the same boat – A talk about Simplaex and Numaferm’s cooperation

Let’s be honest, for a seed investor like HTGF, it’s great when portfolio companies connect and then go on to work together. And that’s exactly what happened with digital agency Ogno, a product of Simplaex, and life sciences company Numaferm. We sat down for a chat with Simplaex co-founder and head Jeff van Ede, his marketing colleague Jesse Bondar, and Christian Schwarz, CEO and co-founder of Numaferm. It resulted in an honest talk about trust, collaboration and how an investor c
18. September 2017
Evonik is investing in NUMAFERM, a specialist in the biotechnological production of peptides
NUMAFERM makes the production of peptides more efficient Investment strengthens Evonik’s growth engines Health & Care and Specialty Additives at Evonik New technical applications are becoming realistic for the first time Through its Venture Capital unit, Evonik has invested in the start-up NUMAFERM and now holds a minority share in the spin-off of Heinrich Heine University Düsseldorf. The investment was made as part of a seed financing round and also includes investments by H
11. May 2017
NUMAFERM revolutionizes peptide production and receives seed financing
The Dusseldorf university spin-off NUMAFERM specializes in the biotechnical production of peptides and is able, through its newly developed platform technology, to dramatically reduce costs for this raw material. For the further technological development and an accelerated market entry, NUMAFERM GmbH is now receiving funding in the seven-digit range. High-Tech Gründerfonds (HTGF), Qiagen co-founders and European Business Angels Prof. Detlev Riesner and Dr. Jürgen Schumacher, as well as the Eur

Info & Contact

Dr. Christian Schwarz


Merowingerplatz 1a
40225 Düsseldorf

In portfolio

28. Apr 2017

HTGF Manager

Dr. Anke Caßing, Principal / Authorized Signatory